Lee Sook-Kyung, Sondgeroth Amy, Xu Yinyan, Warren Joanna, Zhou Shuntai, Gilleece Maria, Hauser Blake M, Gay Cynthia L, Kuruc JoAnn D, Archin Nancie M, Eron Joseph J, Margolis David M, Goonetilleke Nilu, Swanstrom Ronald
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Open Forum Infect Dis. 2024 Apr 17;11(5):ofae212. doi: 10.1093/ofid/ofae212. eCollection 2024 May.
Persistence of HIV-1 in reservoirs necessitates life-long antiretroviral therapy (ART). There are conflicting data using genetic analysis on whether persistence includes an actively replicating reservoir with strong evidence arguing against replication.
We investigated the possibility of ongoing viral evolution during suppressive therapy by comparing near full-length viral genomic sequences using phylogenetic analysis of viral RNA in plasma before therapy initiation early after infection and from virus induced to grow from the latent reservoir after a period of suppressive ART. We also focused our analysis on evidence of selective pressure by drugs in the treatment regimen and at sites of selective pressure by the adaptive immune response.
Viral genomes induced to grow from the latent reservoir from 10 participants with up to 9 years on suppressive ART were highly similar to the nearly homogeneous sequences in plasma taken early after infection at ART initiation. This finding was consistent across the entire genome and when the analysis focused on sites targeted by the drug regimen and by host selective pressure of antibody and cytotoxic T cells. The lack of viral evolution away from pretherapy sequences in spite of demonstrated selective pressure is most consistent with a lack of viral replication during reservoir persistence.
These results do not support ongoing viral replication as a mechanism of HIV-1 persistence during suppressive ART.
HIV-1在病毒储存库中的持续存在使得终身抗逆转录病毒疗法(ART)成为必要。关于持续性是否包括一个活跃复制的储存库,使用基因分析得出的数据相互矛盾,有强有力的证据反对病毒复制。
我们通过对感染后早期治疗开始前血浆中的病毒RNA以及经过一段时间抑制性抗逆转录病毒治疗后从潜伏储存库中诱导生长的病毒进行系统发育分析,比较近乎全长的病毒基因组序列,研究了抑制性治疗期间病毒持续进化的可能性。我们还将分析重点放在治疗方案中药物的选择压力证据以及适应性免疫反应的选择压力位点上。
从10名接受了长达9年抑制性抗逆转录病毒治疗的参与者的潜伏储存库中诱导生长的病毒基因组,与治疗开始时感染后早期采集的血浆中几乎同质的序列高度相似。这一发现贯穿整个基因组,并且当分析聚焦于药物治疗方案以及抗体和细胞毒性T细胞的宿主选择压力所靶向的位点时也是如此。尽管存在明显的选择压力,但与治疗前序列相比缺乏病毒进化,这最符合储存库持续存在期间缺乏病毒复制的情况。
这些结果不支持在抑制性抗逆转录病毒治疗期间,病毒持续复制是HIV-1持续存在的一种机制。